Grant of Options to Directors

RNS Number : 1320D

Alliance Pharma PLC

05 October 2018

 

5 October 2018

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Grant of Options to Directors

Alliance Pharma plc (AIM: APH), the international specialty pharmaceutical group, announces that the Board has issued options over an aggregate of 1,428,000 ordinary shares of 1 pence each in the Company ("Share Options"), on the recommendation of the Company's Remuneration Committee, to the Directors detailed below.

Peter Butterfield, Chief Executive Officer, has been awarded a total of 1,250,000 Share Options. 1,000,000 Share Options have been granted to Mr Butterfield in connection with his appointment on 1 May 2018 as CEO and in recognition of the additional responsibilities that he has assumed. 250,000 have been granted under the Company's 2015 Unapproved Share Option Plan.

Andrew Franklin, Chief Financial Officer, has been awarded a total of 178,000 Share Options pursuant to the Company's 2015 Unapproved Share Option Plan.

The Share Options granted all have an exercise price of 81.6p, being the closing mid-market price on 19  September 2018, the date of announcement of the Company's half year results for 2018, and become exercisable on 19 September 2021, being the third anniversary of the date of the grant, subject to continued employment and the satisfaction of certain performance conditions measured by growth targets in the Company's diluted earnings per share over that three year period.

The net effect of the grant of Share Options and the resultant option holdings are shown in the table below:

Name	Share Options granted	Total no. of options over ordinary shares now held
Peter Butterfield	1,250,000	5,804,803
Andrew Franklin	178,000	2,903,000

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by person discharging managerial responsibilities.

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Mr Peter Butterfield
2	Reason for the notification
a)	Position/status	Chief Executive Officer - Director
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Alliance Pharma plc
b)	Legal Entity Identifier	N/A
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 1.0 pence each ISIN: GB0031030819
b)	Nature of the transaction	Grant of Options
c)	Currency	GBP
d)	Price(s) and volume(s)	Exercise Price (p)	No. of share options
		81.6p	1,250,000
e)	Aggregated information -Aggregated volume - Price - Aggregated total	Grant of 1,250,000 options to acquire shares at £0.816 per share at an aggregate exercise price of £1,020,000
f)	Date of the transaction	5 October 2018
g)	Place of the transaction	London Stock Exchange, AIM

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Mr Andrew Franklin
2	Reason for the notification
a)	Position/status	Chief Financial Officer - Director
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Alliance Pharma plc
b)	Legal Entity Identifier	N/A
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 1.0 pence each ISIN: GB0031030819
b)	Nature of the transaction	Grant of Options
c)	Currency	GBP
d)	Price(s) and volume(s)	Exercise Price (p)	No. of share options
		81.6p	178,000
e)	Aggregated information - Aggregated volume - Price - Aggregated total	Grant of 178,000 options to acquire shares at £0.816 per share at an aggregate exercise price of £145,248
f)	Date of the transaction	5 October  2018
g)	Place of the transaction	London Stock Exchange, AIM

 

END

 

 

DSHUGGPPUUPRUBA